Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers

American Journal of Surgical Pathology

Volumn 29, Issue 3, 2005, Pages 400-406

  Busam, Klaus J ^a   Kucukgöl, Derya ^a   Sato, Eiichi ^a   Frosina, Denise ^a   Teruya Feldstein, Julie ^a   Jungbluth, Achim A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Immunohistochemistry; Melanocyte differentiation; PNL2

Indexed keywords

GLYCOPROTEIN GP 100; MELAN A; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A103; MONOCLONAL ANTIBODY D5; MONOCLONAL ANTIBODY HMB45; MONOCLONAL ANTIBODY PNL2; MONOCLONAL ANTIBODY T311; MONOPHENOL MONOOXYGENASE; UNCLASSIFIED DRUG;

ANGIOMYOLIPOMA; ARTICLE; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; METASTASIS; NERVE SHEATH TUMOR; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; FEMALE; HUMANS; MALE; MELANOCYTES; MELANOMA; NEVUS; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 14644405605     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000152137.81771.5b     Document Type: Article

References (31)

1. Bergman R, Azzam H, Sprecher E, et al. A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas. J Am Acad Dermatol. 2000;42:496-500.
2. Berset M, Cerottini JP, Guggisberg D, et al. Expression of MelanA/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. Int J Cancer. 2001;95:73-77.
3. Busam KJ, Chen YT, Old LJ, et al. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol. 1998;22:976-982.
4. Busam KJ, Iversen K, Coplan KA, et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol. 1998;22:57-63.
5. Busam KJ, Iversen K, Coplan KC, et al. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol. 2001;25:197-204.
6. Busam KJ, Jungbluth AA. Melan-A, a new melanocytic differentiation marker. Adv Anat Pathol. 1999;6:12-18.
7. Chen YT, Stockert E, Jungbluth A, et al. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA. 1996;93:5915-5919.
8. Chen YT, Stockert E, Tsang S, et al. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA. 1995;92:8125-8129.
9. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti- tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol. 2001;54:196-200.
10. de Vries TJ, Smeets M, de Graaf R, et al. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol. 2001;193:13-20.
11. Fetsch PA, Filie AC, Steinberg SM, et al. Comparison of antibodies to MART-1 and MelanA in fine-needle aspiration samples of metastatic malignant melanoma. Diagn Cytopathol. 2001;25:78-79.
12. Fetsch PA, Marincola FM, Abati A. The new melanoma markers: MART-1 and Melan-A (the NIH experience). Am J Surg Pathol. 1999;23:607-610.
13. Fetsch PA, Marincola FM, Filie A, et al. Melanoma-associated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration. Cancer. 1999;87:37-42.
14. Fetsch PA, Riker AI, Marincola FM, et al. Tyrosinase immunoreactivity in fine-needle aspiration samples of metastatic malignant melanoma. Cancer. 2000;90:252-257.
15. Griffin MC, Robinson RA, Trask DK. Validation of tissue microarrays using p53 immunohistochemical studies of squamous cell carcinoma of the larynx. Mod Pathol 2003;16:1181-1188.
16. Hemesath TJ, Price ER, Takemoto C, et al. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature. 1998;391:298-301.
17. Hofbauer GF, Kamarashev J, Geertsen R, et al. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res. 1998;8:337-343.
18. Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol. 2001;158:1245-1251.
19. Jungbluth AA, Busam KJ, Gerald WL, et al. A103: An anti-melana monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol. 1998;22:595-602.
20. Jungbluth AA, Iversen K, Coplan K, et al. T311-an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. Pathol Res Pract. 2000;196:235-242.
21. Jungbluth AA, Iversen K, Coplan K, et al. Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas. An immunohistochemical and rt-PCR analysis. Virchows Arch. 1999;434:429-435.
22. Jungbluth AA, King R, Fisher DE, et al. Immunohistochemical and reverse transcription-polymerase chain reaction expression analysis of tyrosinase and microphthalmia-associated transcription factor in angiomyolipomas. Appl Immunohistochem Mol Morphol. 2001;9:29-34.
23. Kaiserling E, Krober S, Xiao JC, et al. Angiomyolipoma of the kidney. Immunoreactivity with HMB-45. Light- and electron-microscopic findings. Histopathology. 1994;25:41-48.
24. King R, Googe PB, Weilbaecher KN, et al. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol. 2001;25:51-57.
25. King R, Weilbaecher KN, McGill G, et al. Microphthalmia transcription factor: a sensitive and specific melanocyte marker for melanoma diagnosis. Am J Pathol. 1999;155:731-738.
26. Makhlouf HR, Ishak KG, Shekar R, et al. Melanoma markers in angiomyolipoma of the liver and kidney: a comparative study. Arch Pathol Lab Med. 2002;126:49-55.
27. Miller AJ, Du J, Rowan S, et al. Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res. 2004;64:509-516.
28. Prasad ML, Jungbluth AA, Iversen K, et al. Expression of melanocytic differentiation markers in malignant melanomas of the oral and sinonasal mucosa. Am J Surg Pathol. 2001;25:782-787.
29. Rochaix P, Lacroix-Triki M, Lamant L, et al. PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen. Mod Pathol. 2003;16:481-490.
30. Tuna EB, Lebe B, Yorukoglu K. HMB 45 and melan-A expression in renal angiomyolipoma and their significance for the diagnosis. Tumori. 2003;89:46-48.
31. Zavala-Pompa A, Folpe AL, Jimenez RE, et al. Immunohistochemical study of microphthalmia transcription factor and tyrosinase in angiomyolipoma of the kidney, renal cell carcinoma, and renal and retroperitoneal sarcomas: comparative evaluation with traditional diagnostic markers. Am J Surg Pathol. 2001;25:65-70.